Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.900
+0.050 (1.75%)
At close: Apr 28, 2026, 4:00 PM EDT
2.810
-0.090 (-3.10%)
After-hours: Apr 28, 2026, 6:17 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,852,321
Market Cap
68.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| iBio, Inc. | 20 |
| ImageneBio | 15 |
| Annovis Bio | 7 |
| MediciNova | 6 |
ACTU News
- 6 days ago - Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - Reuters
- 14 days ago - Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 5 weeks ago - Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Accesswire
- 7 weeks ago - Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - GlobeNewsWire
- 2 months ago - Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire